JPMorgan analyst Jared Dinges keeps a Neutral rating on British American Tobacco after the FDA issued Marketing Denial Orders for the company’s leading Vuse Alto e-cigarette brand. The news is “incrementally unhelpful” and likely to pressure the shares initially, the analyst tells investors in a research note. However, the firm believes the FDA denial for Vuse Alto menthol was already anticipated by investors. As such, British American Tobacco shares may see “some gradual relief” following the initial selloff, says JPMorgan.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on BTI:
- FDA denies marketing of six flavored Vuse Alto e-cigarette products
- FDA to ban Vuse menthol e-cigarette sales, WSJ reports
- Yielding 9.2%, British American Stock (NYSE:BTI) Looks Better Than Ever
- GCOW: An ETF for Dividend and Free Cash Flow Lovers
- TD Cowen puts $33 target on U.S. shares of British American Tobacco